TY - JOUR
T1 - Antiprotozoal agents
T2 - How have they changed over a decade?
AU - Fernandes, Vitória de Souza
AU - da Rosa, Rafael
AU - Zimmermann, Lara A.
AU - Rogério, Kamilla R.
AU - Kümmerle, Arthur E.
AU - Bernardes, Lilian S. C.
AU - Graebin, Cedric S.
N1 - Publisher Copyright:
© 2021 Deutsche Pharmazeutische Gesellschaft
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Neglected tropical diseases are a diverse group of communicable diseases that are endemic in low- or low-to-middle-income countries located in tropical and subtropical zones. The number and availability of drugs for treating these diseases are low, the administration route is inconvenient in some cases, and most of them have safety, efficacy, or adverse/toxic reaction issues. The need for developing new drugs to deal with these issues is clear, but one of the most drastic consequences of this negligence is the lack of interest in the research and development of new therapeutic options among major pharmaceutical companies. Positive changes have been achieved over the last few years, although the overall situation remains alarming. After more than one decade since the original work reviewing antiprotozoal agents came to light, now it is time to question ourselves: How has the scenario for the treatment of protozoal diseases such as malaria, leishmaniasis, human African trypanosomiasis, and American trypanosomiasis changed? This review covers the last decade in terms of the drugs currently available for the treatment of these diseases as well as the clinical candidates being currently investigated.
AB - Neglected tropical diseases are a diverse group of communicable diseases that are endemic in low- or low-to-middle-income countries located in tropical and subtropical zones. The number and availability of drugs for treating these diseases are low, the administration route is inconvenient in some cases, and most of them have safety, efficacy, or adverse/toxic reaction issues. The need for developing new drugs to deal with these issues is clear, but one of the most drastic consequences of this negligence is the lack of interest in the research and development of new therapeutic options among major pharmaceutical companies. Positive changes have been achieved over the last few years, although the overall situation remains alarming. After more than one decade since the original work reviewing antiprotozoal agents came to light, now it is time to question ourselves: How has the scenario for the treatment of protozoal diseases such as malaria, leishmaniasis, human African trypanosomiasis, and American trypanosomiasis changed? This review covers the last decade in terms of the drugs currently available for the treatment of these diseases as well as the clinical candidates being currently investigated.
UR - http://www.scopus.com/inward/record.url?scp=85117252254&partnerID=8YFLogxK
U2 - 10.1002/ardp.202100338
DO - 10.1002/ardp.202100338
M3 - Review article
C2 - 34661935
AN - SCOPUS:85117252254
SN - 0365-6233
VL - 355
JO - Archiv der Pharmazie
JF - Archiv der Pharmazie
IS - 2
M1 - 2100338
ER -